Efficacy of trelagliptin for glucose fluctuation, oxidative stress and inflammation in patients with type 2 diabetes mellitus.
Not Applicable
- Conditions
- Patients with type 2 diabetes
- Registration Number
- JPRN-UMIN000018334
- Lead Sponsor
- Ise Red Cross Hospital Department of Metabolic Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Type 1 diabetes 2) Had ketosis or coma within 6 month 3) Secondary diabetes 4) Patients receiving insulin or GLP-1 analogue therapy 5) Poor-controlled diabetes (HbA1c>10.0 % or fasting blood glucose levels>250mg/dl) 6) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 7) Either level of aspartate aminotransaminase or alanine aminotransferase exceed three-fold of the normal limits 8) Renal insufficiency: serum creatinine>1.5 or Ccr<50ml/min 9) Malignancies or other diseases with poor prognosis 10) Pregnant 11) Subjects whose doctor in charge do not agree to join the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method